Genmab and Seagen’s TIVDAK trial meets primary endpoint

Genmab and Seagen have reported that the Phase III innovaTV 301/ENGOT cx-12/GOG 3057 trial of TIVDAK (tisotumab vedotin-tftv) for the treatment of recurrent or metastatic cervical cancer has met its primary endpoint of overall survival (OS).